Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws
Corresponding Author
J Bagan
Oral Medicine, Head Service of Stomatology and Maxillofacial Surgery, University of Valencia, University General Hospital, Valencia, Spain
Correspondence: Jose Bagan, Oral Medicine Department, Stomatology and Maxillofacial Service, University General Hospital, Avda/Tres Cruces s/n, 46014 Valencia, Spain. Tel/Fax: 34 961972127, E-mail: [email protected]Search for more papers by this authorGT Sáez
Biochemistry and Molecular Biology, Department of Biochemistry, School of Medicine, University of Valencia, CIBERobn, Servicio de Análisis Clínicos-CDBI, HGUV, Valencia, Spain
Search for more papers by this authorMC Tormos
Department of Biochemistry and Molecular Biology, School of Medicine, University of Valencia, CIBERobn, Valencia, Spain
Search for more papers by this authorE Hens
Oral and Maxillofacial Surgery, University General Hospital, Valencia, Spain
Search for more papers by this authorMJ Terol
Hematology, Service of Oncohematology, University Clinic Hospital, Valencia, Spain
Search for more papers by this authorJM Diaz-Fernández
Oral and Maxillofacial Surgery, University General Hospital, Valencia, Spain
Search for more papers by this authorA Lluch
Oncology, Head Service of Oncohematology, University Clinic Hospital, Valencia, Spain
Search for more papers by this authorC Camps
Oncology, Head Service of Oncology, University General Hospital, Valencia, Spain
Search for more papers by this authorCorresponding Author
J Bagan
Oral Medicine, Head Service of Stomatology and Maxillofacial Surgery, University of Valencia, University General Hospital, Valencia, Spain
Correspondence: Jose Bagan, Oral Medicine Department, Stomatology and Maxillofacial Service, University General Hospital, Avda/Tres Cruces s/n, 46014 Valencia, Spain. Tel/Fax: 34 961972127, E-mail: [email protected]Search for more papers by this authorGT Sáez
Biochemistry and Molecular Biology, Department of Biochemistry, School of Medicine, University of Valencia, CIBERobn, Servicio de Análisis Clínicos-CDBI, HGUV, Valencia, Spain
Search for more papers by this authorMC Tormos
Department of Biochemistry and Molecular Biology, School of Medicine, University of Valencia, CIBERobn, Valencia, Spain
Search for more papers by this authorE Hens
Oral and Maxillofacial Surgery, University General Hospital, Valencia, Spain
Search for more papers by this authorMJ Terol
Hematology, Service of Oncohematology, University Clinic Hospital, Valencia, Spain
Search for more papers by this authorJM Diaz-Fernández
Oral and Maxillofacial Surgery, University General Hospital, Valencia, Spain
Search for more papers by this authorA Lluch
Oncology, Head Service of Oncohematology, University Clinic Hospital, Valencia, Spain
Search for more papers by this authorC Camps
Oncology, Head Service of Oncology, University General Hospital, Valencia, Spain
Search for more papers by this authorAbstract
Aim
To determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL-6.
Material and Methods
We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL-6 samples using an ELISA test.
Results
Significantly, higher IL-6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P < 0.01). Group 1 showed no differences in plasma or saliva IL-6 according to patient gender (P > 0.05), type of tumor, BRONJ location, etiology of BRONJ, or disease stage (P > 0.05). We found higher plasma and saliva IL-6 values in the more advances stages of BRONJ, although the differences were not statistically significant.
Conclusions
Plasma and saliva IL-6 values were higher in our patients with BRONJ than in controls and therefore might be a useful tool for monitoring the severity of BRONJ.
References
- Arduino PG, Menegatti E, Scoletta M et al (2011). Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med 40: 510–515.
- Bagan J, Scully C, Sabater V, Jimenez Y (2009a). Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 45: 551–554.
- Bagan JV, Jiménez Y, Hernández S et al (2009b). Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: a comparative study. Med Oral Patol Oral Cir Bucal 14: e616–e619.
- Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L (2012). Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol 48: 753–757.
- Bagan J, Sheth CC, Soria JM, Margaix M, Bagan L (2013). Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. J Oral Pathol Med 42: 405–408.
- Belibasakis GN, Johansson A, Wang Y et al (2005). Cytokine responses of human gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending toxin. Cytokine 30: 56–63.
- Cetiner S, Sucak GT, Kahraman SA et al (2009). Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 27: 435–443.
- Epstein MS, Ephros HD, Epstein JB (2012). Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol [Epub ahead of print]. PMID: 22901640.
- Favia G, Pilolli GP, Maiorano E (2009). Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406–413.
- Fedele S, Porter SR, D'Aiuto F et al (2010). Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123: 1060–1064.
- Guiliani N, Pedrazzoni M, Passeri G, Girasole G (1998). Bisphosphonates inhibit IL-6 production of human osteoblast-like cells. Scand J Rheumatol 27: 38–41.
- Hansen T, Kunkel M, Springer E et al (2007). Actinomycosis of the jaws–histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451: 1009–1017.
- Junquera L, Gallego L, Pelaz A, Olay S (2009). Oral bisphosphonates-associated osteonecrosis in rheumatoid arthritis. Med Oral Patol Oral Cir Bucal 14: E292–E294.
- Kos M, Brusco D, Kuebler J, Engelke W (2010). Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int J Oral Maxillofac Surg 39: 1097–1102.
- Kyrgidis A, Koloutsos G, Vahtsevanos K (2009). Treatment protocols of bisphosphonate-related osteonecrosis of the jaws. Head Neck 31: 1112–1113.
- Margaix-Muñoz M, Bagan J, Poveda-Roda R (2013). Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition. Med Oral Patol Oral Cir Bucal 18: e194–e200.
- Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115–1117.
- Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567–1575.
- Matsuki Y, Yamamoto T, Hara K (1992). Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 76: 42–47.
- Matsushima K, Ohbayashi E, Takeuchi H, Hosoya S, Abiko Y, Yamazaki M (1998). Stimulation of interleukin-6 production in human dental pulp cells by peptidoglycans from Lactobacillus casei. J Endod 24: 252–255.
- Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R (2000). A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 109: 661–664.
- Mozzati M, Martinasso G, Maggiora M et al (2013). Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. Clin Oral Investig 17: 1259–1266.
- Navazesh M (1993). Methods for collecting saliva. Ann N Y Acad Sci 694: 72–77.
- Nibali L, Fedele S, D'Aiuto F, Donos N (2012). Interleukin-6 in oral diseases: a review. Oral Dis 18: 236–243.
- Nishimoto N (2010). Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 87: 483–487.
- O'Ryan FS, Lo JC (2012). Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 70: 1844–1853.
- Otto S, Schreyer C, Hafner S et al (2012). Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40: 303–309.
- Packard RR, Libby P (2008). Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54: 24–38.
- Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007). Plasma leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36: 101–106.
- Pazianas M (2011). Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103: 232–240.
- Reid IR, Cornish J (2011). Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8: 90–96.
- Playfair JHL, Chain BM (2013). Immunology at a Glance, 9th edn. Oxford: Wiley-Blackwell.
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 35: 119–130.
- Sarasquete ME, González M, San Miguel JF, García-Sanz R (2009). Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15: 382–387.
- Sharma M, Bairy I, Pai K et al (2011). Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis. Clin Oral Investig 15: 705–714.
- Silness J, Löe H (1964). Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22: 121–135.
- Such E, Cervera J, Terpos E et al (2011). CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica 96: 1557–1559.
- Svatun B, Helöe LA (1975). Dental status and treatment needs among institutionalized mentally subnormal persons in Norway. Community Dent Oral Epidemiol 3: 208–213.
- Tipton DA, Seshul BA, Dabbous MKh (2011). Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J Periodontal Res 46: 39–47.
- Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M (2012). Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78: c85.
- Vescovi P, Campisi G, Fusco V et al (2011). Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47: 191–194.
- Viereck V, Emons G, Lauck V (2002). Bisphosphonates pamidronate and zoledronic acid stimulated osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680–686.
